Foghorn Therapeutics (FHTX) Non-Current Deffered Revenue (2020 - 2026)

Foghorn Therapeutics' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $193.6 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 12.97% year-over-year to $193.6 million; the TTM figure through Mar 2026 stood at $193.6 million (down 12.97% YoY), while the FY2025 annual figure was $206.0 million, down 12.15% from the prior year.
• Non-Current Deffered Revenue was $193.6 million for Q1 2026 at Foghorn Therapeutics, down from $206.0 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $317.1 million in Q1 2022 to a low of $193.1 million in Q3 2025.
• Historically, Non-Current Deffered Revenue has averaged $259.5 million across 5 years, with a median of $266.1 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue soared 16324.84% in 2022, then fell 22.62% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $304.0 million in 2022, then declined by 11.8% to $268.1 million in 2023, then fell by 12.55% to $234.5 million in 2024, then retreated by 12.15% to $206.0 million in 2025, then fell by 6.01% to $193.6 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $193.6 million (Q1 2026), $206.0 million (Q4 2025), and $193.1 million (Q3 2025), per Business Quant data.